Dendritic cell vaccination in medullary thyroid carcinoma
/in Dendritic Cells, International Publications, Thyroid CancerCharacterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis
/in Dendritic Cells, International Publications, Soft Tissue SarcomaGeneration of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides
/in Colorectal Cancer, Dendritic Cells, International PublicationsCytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaThe role of idiotype vaccines in the treatment of human B-cell malignancies
/in International Publications, Malignant Lymphoma[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)]
/in Hyperthermia, International Publications, Malignant Pleural MesotheliomaWhole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer
/in Hyperthermia, International Publications, Ovarian CancerEnhancement of antitumor response to sarcoma 45 in rats by combination of whole-body hyperthermia and interleukin-2
/in Hyperthermia, International Publications, Soft Tissue SarcomaMicronutrient concentrations in patients with malignant disease: effect of the inflammatory response
/in International Publications, Micronutrients
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer